GRTX vs. LCI, BOLT, RVPH, ACST, NNVC, BIVI, BIOR, NRXP, UBX, and COCP
Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Lannett (LCI), Bolt Biotherapeutics (BOLT), Reviva Pharmaceuticals (RVPH), Acasti Pharma (ACST), NanoViricides (NNVC), BioVie (BIVI), Biora Therapeutics (BIOR), NRx Pharmaceuticals (NRXP), Unity Biotechnology (UBX), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical preparations" industry.
Lannett (NYSE:LCI) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.
Galera Therapeutics has a net margin of 0.00% compared to Galera Therapeutics' net margin of -62.40%.
40.3% of Lannett shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 13.1% of Lannett shares are owned by insiders. Comparatively, 6.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Galera Therapeutics has lower revenue, but higher earnings than Lannett. Galera Therapeutics is trading at a lower price-to-earnings ratio than Lannett, indicating that it is currently the more affordable of the two stocks.
Lannett has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.
Lannett received 410 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 59.13% of users gave Lannett an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote.
In the previous week, Galera Therapeutics had 1 more articles in the media than Lannett. MarketBeat recorded 1 mentions for Galera Therapeutics and 0 mentions for Lannett. Galera Therapeutics' average media sentiment score of 0.00 equaled Lannett'saverage media sentiment score.
Summary
Lannett and Galera Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Galera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galera Therapeutics Competitors List
Related Companies and Tools
